• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma.

作者信息

Alqahtani Saleh A, Sanai Faisal M, Alolayan Ashwaq, Abaalkhail Faisal, Alsuhaibani Hamad, Hassanain Mazen, Alhazzani Waleed, Alsuhaibani Abdullah, Algarni Abdullah, Forner Alejandro, Finn Richard S, Al-Hamoudi Waleed K

机构信息

Liver Transplant Centre, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia; Division of Gastroenterology and Hepatology, Johns Hopkins University, Baltimore, Maryland, United States.

Liver Disease Research Center, College of Medicine, King Saud University, Riyadh; Department of Medicine, Gastroenterology Unit, King Abdulaziz Medical City, Jeddah, Saudi Arabia.

出版信息

Saudi J Gastroenterol. 2020 Oct;26(Suppl 1):S1-S40. doi: 10.4103/sjg.SJG_477_20.

DOI:10.4103/sjg.SJG_477_20
PMID:33078723
原文链接:
https://pmc.ncbi.nlm.nih.gov/articles/PMC7768980/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83fb/7768980/bfd945e547f5/SJG-26-1-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83fb/7768980/b89f1b24afd1/SJG-26-1-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83fb/7768980/1854b9365ed5/SJG-26-1-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83fb/7768980/bfd945e547f5/SJG-26-1-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83fb/7768980/b89f1b24afd1/SJG-26-1-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83fb/7768980/1854b9365ed5/SJG-26-1-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83fb/7768980/bfd945e547f5/SJG-26-1-g003.jpg

相似文献

1
Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma.沙特肝脏疾病与移植研究协会肝细胞癌诊断与管理实践指南
Saudi J Gastroenterol. 2020 Oct;26(Suppl 1):S1-S40. doi: 10.4103/sjg.SJG_477_20.
2
Saudi guidelines for the diagnosis and management of hepatocellular carcinoma: technical review and practice guidelines.沙特肝细胞癌诊断与管理指南：技术审查与实践指南
Ann Saudi Med. 2012 Mar-Apr;32(2):174-99. doi: 10.5144/0256-4947.2012.174.
3
Saudi Gastroenterology Association guidelines for the diagnosis and management of hepatocellular carcinoma: summary of recommendations.沙特胃肠病学协会肝细胞癌诊断与管理指南：推荐摘要
Ann Saudi Med. 2006 Jul-Aug;26(4):261-5. doi: 10.5144/0256-4947.2006.261.
4
[Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)].《中国原发性肝癌诊疗规范（2019年版）》
Zhonghua Gan Zang Bing Za Zhi. 2020 Feb 20;28(2):112-128. doi: 10.3760/cma.j.issn.1007-3418.2020.02.004.
5
[Strategies for the management of hepatocellular carcinoma recommended by the American Association for the Study of Liver Diseases].[美国肝病研究协会推荐的肝细胞癌管理策略]
Zhonghua Gan Zang Bing Za Zhi. 2006 Jul;14(7):556-7.
6
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases.肝细胞癌的诊断、分期及管理：美国肝病研究协会2018年实践指南
Hepatology. 2018 Aug;68(2):723-750. doi: 10.1002/hep.29913.
7
Hepatocellular carcinoma (primary cancer of the liver).肝细胞癌（原发性肝癌）。
Gastroenterol Clin Biol. 2006 Sep;30 Spec No 2:2S57-2S61.
8
Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults.成人肝细胞癌（HCC）诊断和治疗指南
Gut. 2003 May;52 Suppl 3(Suppl 3):iii1-8. doi: 10.1136/gut.52.suppl_3.iii1.
9
[Updated guide for diagnosis, staging and treatment of hepatocellular carcinoma].[肝细胞癌诊断、分期及治疗更新指南]
Med Clin (Barc). 2007 May 19;128(19):741-8. doi: 10.1157/13106134.
10
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.欧洲肝脏研究学会-欧洲肿瘤内科学会临床实践指南：肝细胞癌的管理
J Hepatol. 2012 Apr;56(4):908-43. doi: 10.1016/j.jhep.2011.12.001.

引用本文的文献

1
Survival Outcomes and Prognostic Factors of Systemic Therapy for Advanced Hepatocellular Carcinoma: A Multidisciplinary Clinic Experience from Saudi Arabia.晚期肝细胞癌全身治疗的生存结果及预后因素：沙特阿拉伯的多学科临床经验
J Hepatocell Carcinoma. 2025 Jul 23;12:1623-1632. doi: 10.2147/JHC.S525984. eCollection 2025.
2
Transarterial Chemoembolization Outperforms Radioembolization in Early- and Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Retrospective Study.经动脉化疗栓塞术在早期和中期肝细胞癌治疗中优于放射性栓塞术：一项多中心回顾性研究
Cancers (Basel). 2025 Jul 7;17(13):2254. doi: 10.3390/cancers17132254.
3

本文引用的文献

1
Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040.纳武利尤单抗联合伊匹单抗治疗索拉非尼治疗后晚期肝细胞癌患者：CheckMate 040 的 5 年结果。
Ann Oncol. 2024 Jun;35(6):537-548. doi: 10.1016/j.annonc.2024.03.005. Epub 2024 May 22.
2
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.仑伐替尼联合帕博利珠单抗治疗不可切除肝细胞癌的 Ib 期研究。
J Clin Oncol. 2020 Sep 10;38(26):2960-2970. doi: 10.1200/JCO.20.00808. Epub 2020 Jul 27.
3
Scientific Rationale for Combination Immunotherapy of Hepatocellular Carcinoma with Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies.
Surgical treatment for hepatocellular carcinoma in era of multidisciplinary strategies.
多学科策略时代的肝细胞癌外科治疗
Int J Clin Oncol. 2025 Mar;30(3):417-426. doi: 10.1007/s10147-025-02703-7. Epub 2025 Feb 5.
4
Multisociety consensus recommendations on hepatitis delta virus infection.关于丁型肝炎病毒感染的多学会共识建议。
Saudi J Gastroenterol. 2025 Jan 1;31(1):5-13. doi: 10.4103/sjg.sjg_322_24. Epub 2024 Dec 5.
5
Nivolumab as Second-Line Therapy Improves Survival in Patients with Unresectable Hepatocellular Carcinoma.纳武利尤单抗作为二线治疗可改善不可切除肝细胞癌患者的生存率。
Cancers (Basel). 2024 Jun 11;16(12):2196. doi: 10.3390/cancers16122196.
6
Treatment Patterns and Recommendations for Improving the Management of Hepatocellular Carcinoma in Saudi Arabia.沙特阿拉伯肝细胞癌治疗模式及改善管理的建议
J Hepatocell Carcinoma. 2024 Feb 16;11:349-362. doi: 10.2147/JHC.S442842. eCollection 2024.
7
SASLT guidelines: Update in treatment of hepatitis C virus infection, 2024.《SASLT 指南：2024 年丙型肝炎病毒感染治疗更新》。
Saudi J Gastroenterol. 2024 Jan 1;30(Supp 1):S1-S42. doi: 10.4103/sjg.sjg_333_23. Epub 2024 Jan 3.
8
Surveillance and treatment of primary hepatocellular carcinoma (aka. STOP HCC): protocol for a prospective cohort study of high-risk patients for HCC using GALAD-score.原发性肝细胞癌的监测和治疗（又名 STOP HCC）：使用 GALAD-score 对 HCC 高危患者进行前瞻性队列研究的方案。
BMC Cancer. 2023 Sep 18;23(1):875. doi: 10.1186/s12885-023-11167-9.
9
How Could Different Obesity Scenarios Alter the Burden of Type 2 Diabetes and Liver Disease in Saudi Arabia?不同肥胖情景如何改变沙特阿拉伯 2 型糖尿病和肝病负担？
Obes Facts. 2023;16(6):559-566. doi: 10.1159/000533301. Epub 2023 Aug 8.
10
The future health and economic burden of obesity-attributable type 2 diabetes and liver disease among the working-age population in Saudi Arabia.沙特阿拉伯工作年龄人群中肥胖导致的 2 型糖尿病和肝脏疾病的未来健康和经济负担。
PLoS One. 2022 Jul 14;17(7):e0271108. doi: 10.1371/journal.pone.0271108. eCollection 2022.
肝细胞癌抗PD-1/PD-L1和抗CTLA-4抗体联合免疫治疗的科学原理
Liver Cancer. 2019 Nov;8(6):413-426. doi: 10.1159/000503254. Epub 2019 Sep 27.
4
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌。
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
5
The Rising Threat of Hepatocellular Carcinoma in the Middle East and North Africa Region: Results From Global Burden of Disease Study 2017.中东和北非地区肝细胞癌日益增长的威胁：2017年全球疾病负担研究结果
Clin Liver Dis (Hoboken). 2020 Jan 29;14(6):219-223. doi: 10.1002/cld.890. eCollection 2019 Dec.
6
Comparison of extracellular and hepatobiliary MR contrast agents for the diagnosis of small HCCs.用于诊断小肝癌的细胞外和肝胆磁共振造影剂的比较
J Hepatol. 2020 May;72(5):937-945. doi: 10.1016/j.jhep.2019.12.011. Epub 2019 Dec 21.
7
Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.随机、多中心前瞻性试验：比较经动脉化疗栓塞（TACE）联合索拉非尼与单纯 TACE 治疗肝细胞癌患者的疗效：TACTICS 试验。
Gut. 2020 Aug;69(8):1492-1501. doi: 10.1136/gutjnl-2019-318934. Epub 2019 Dec 4.
8
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial.帕博利珠单抗作为 KEYNOTE-240 中晚期肝细胞癌二线治疗的疗效：一项随机、双盲、III 期试验。
J Clin Oncol. 2020 Jan 20;38(3):193-202. doi: 10.1200/JCO.19.01307. Epub 2019 Dec 2.
9
Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma.联合选择性内部放射治疗和索拉非尼对晚期肝细胞癌患者生存的影响。
J Hepatol. 2019 Dec;71(6):1164-1174. doi: 10.1016/j.jhep.2019.08.006. Epub 2019 Aug 14.
10
Immunotherapy for hepatocellular carcinoma: Current and future.肝细胞癌的免疫治疗：现状与未来。
World J Gastroenterol. 2019 Jun 28;25(24):2977-2989. doi: 10.3748/wjg.v25.i24.2977.